International Rectifier Corporation (NYSE:IRF), a world leader in power management technology, today announced the introduction of the M3G120 Series of 40W radiation-hardened (RAD-Hard) 120V input DC-DC converters for a wide range of digital and analog satellite power systems requiring up to 15 years or more of mission life such as space stations and NASA’s Orion MPCV (Multi-Purpose Crew Vehicle) programs. International Rectifier Corporation (NYSE:IRF) belongs to Technology sector. Its net profit margin is 3.60% and weekly performance is -2.63%. On last trading day company shares ended up $25.20. International Rectifier Corporation (NYSE:IRF) distance from 50-day simple moving average (SMA50) is -8.38%.

Globus Medical Inc (NYSE:GMED) announced its second-quarter financial results for fiscal’14 (2QFY14; ended June 30) yesterday. The company reported global sales of $113.6 million, up 6.1% year-over-year (YoY). The Street, however, expected revenues to total $119.9 million for the three-month period. Adjusted earnings per share (EPS) were $0.23 – in line with analysts’ prediction. Globus’s net income came in at $20.6 million, growing from $7.4 million in the second quarter last year. Globus Medical, Inc. (NYSE:GMED) shares fell -17.95% in last trading session and ended the day at $18.51. GMED Gross Margin is 77.30% and its return on assets is 12.80%. Globus Medical, Inc. (NYSE:GMED) quarterly performance is -22.58%.

Acadia Healthcare Company, Inc. (NASDAQ:ACHC), a Tennessee-based behavioral health provider, plans to build a 120-bed facility at the site, according to Building Department records. On 06 August, Acadia Healthcare Company, Inc. (NASDAQ:ACHC) shares moved up 0.19% and was closed at $47.68. ACHC EPS growth in last 5 year was 63.10%. Acadia Healthcare Company, Inc. (NASDAQ:ACHC) year to date (YTD) performance is 0.74%.

CEL-SCI Corp. (NYSEMKT:CVM) announced that during the month of July the Company enrolled 14 patients with advanced primary, not yet treated, head and neck cancer into its global pivotal Phase III head and neck cancer trial for its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection). A total of 47 patients were enrolled over the past three months, with 14 in May, 19 in June, and 14 in July. This marks a 15% increase over the prior three month period when a total of 41 patients were enrolled. CEL-SCI Corporation (NYSEMKT:CVM) ended the last trading day at $1.07. Company weekly volatility is calculated as 6.16%and price to cash ratio as 6.66. CEL-SCI Corporation (NYSEMKT:CVM) showed a weekly performance of -5.31%.

Mellanox Technologies Ltd (NASDAQ:MLNX) was upgraded by Barclays from an “underweight” rating to an “equal weight” rating in a research note issued on Monday. The firm currently has a $45.00 target price on the stock, up from their previous target price of $36.00. Barclays’ target price would indicate a potential upside of 7.37% from the company’s current price. Mellanox Technologies, Ltd. (NASDAQ:MLNX) shares fell -0.52% in last trading session and ended the day on $41.69. MLNX Gross Margin is 65.40% and its return on assets is -4.10%. Mellanox Technologies, Ltd. (NASDAQ:MLNX) quarterly performance is 26.83%.